Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NextCell's largest shareholder Diamyd Medical exercise all of its warrants

Stem cell company NextCell Pharma AB ("NXTCL") announces today, that its largest shareholder, Diamyd Medical AB, will exercise all its 296 800 series TO1 warrants. Diamyd will exercise the warrants during the subscription period which runs during the period 23rd August – 13th September 2018. This represents an investment total of SEK 1 484 000, corresponding to approximately 10 % of the outstanding warrants.The diabetes Company Diamyd Medical is one of the main owners of NextCell Pharma, with a shareholding of approximately 14 %. In addition to its current shares, Diamyd Medical also has

Polygiene AB (publ.) Interim Report 1 Januari–30 June 2018

Strong growth in April and May and earnings improveQ2 in brief · In the second quarter, net sales were to MSEK 16.6 (14.6), which corresponds to a 14% increase compared to the same period last year. · The operating profit/loss (EBIT) for the period improved compared to the same period last year and amounted to MSEK -1.9 (-3.7). · Cash flow for the second quarter was MSEK -4.2 (-3.5). · The gross margin amounted to 63% (65%). ·  Strong growth during the first two months of the quarter temporarily slackened off in June. The third quarter initially shows signs of strong growth.

ChromoGenics receives order of approximately 220 sqm ConverLight® dynamic glass to Åke Sundvall

ChromoGenics AB (publ) has signed an agreement with Åke Sundvall Byggnads AB to deliver ConverLight® to the project Knäckepilen in Uppsala.ChromoGenics has signed an agreement to deliver approximately 220 sqm of dynamic glass to the project Knäckepilen at Gränbystaden in Uppsala, where Åke Sundvall builds condominiums. ConverLight® will be delivered during the second half of 2018, and time for moving in to the apartments is scheduled for the first quarter of 2019. "People need daylight. In the project Knäckepilen we have focused on innovative architecture and integrated large glass

Interim report second quarter 2018

During the second quarter 2018 sales for PowerCell Sweden AB (publ) more than doubled from MSEK 6.0 to MSEK 13.5 compared to the same period last year, driven by increased customer activities and orders. Operating income for the period was MSEK -19.3 (-18.0).“The awareness about the acute climate situation is increasing and driving interest in us and our products”, Per Wassén, CEO of PowerCell said. “At the same time we continue our structured work to step by step build the company to be better able to both support and to benefit from the necessary transformation.”The English version is

Interim report April - June 2018

Second quarter · Net sales amounted to MSEK 6.1 (28.5)  · EBITDA amounted to MSEK -1.7 (2.3)  · EBIT amounted to MSEK -3.9 (-2.8)  · EBT amounted to MSEK -4.0 (-5.5)  · Earnings per share before dilutions amounted to SEK -0.08 (-0.15)  · Listed on Oslo Stock Exchange, Merkur Market  First half year · Net sales amounted to MSEK 13.6 (57.6)  · EBITDA amounted to MSEK -5.9 (4.3)  · EBIT amounted to MSEK -10.3 (-5.7)  · EBT amounted to MSEK -14.4 (-11.3)  · Earnings per share before dilutions amounted to SEK -0.31 (-0.33)  Significant events after the

Resurs Bank issues SEK 700 million of senior unsecured bonds

Resurs Bank AB, a wholly owned subsidiary of Resurs Holding AB (Nasdaq Stockholm: RESURS), has issued SEK 700 million of senior unsecured bonds in the Nordic market. The 3 year bonds (with maturity August 2021) will be listed on Nasdaq Stockholm. The offer attracted very strong demand and resulted in an oversubscribed orderbook.The bonds are issued under Resurs Bank’s MTN programme with a total frame of SEK 8 billion and pays a coupon of 3m Stibor + 1.50%. Settlement date will be 30 August 2018 and maturity date 30 August 2021.Nordea and Swedbank acted as joint book runners in the

Resurs Bank issues SEK 700 million of senior unsecured bonds

Resurs Bank AB has issued SEK 700 million of senior unsecured bonds in the Nordic market. The 3 year bonds (with maturity August 2021) will be listed on Nasdaq Stockholm. The offer attracted very strong demand and resulted in an oversubscribed orderbook.The bonds are issued under Resurs Bank’s MTN programme with a total frame of SEK 8 billion and pays a coupon of 3m Stibor + 1.50%. Settlement date will be 30 August 2018 and maturity date 30 August 2021.Nordea and Swedbank acted as joint book runners in the transaction. For additional information:Peter Rosén, CFO & Head of IR, peter.

Interim Report Q2 2018: Strong EPS growth and rapid revenue growth in the US

Second quarter 2018 · Revenue increased to SEK 48.1 (42.7) million. Revenue from affiliate operations rose to SEK 47.4 (40.3) million. · EBITDA increased to SEK 30.5 (25.9) million and was negatively impacted by SEK 0.7 million in expenses attributable to switching its listing to Nasdaq First North Premier. · Profit after tax rose to SEK 22.0 (8.0) million. · Earnings per share increased to SEK 0.31 (0.13). · Total NDC growth increased 21%; largest vertical Casino increased the number of NDCs by 36%. First half 2018 · Revenue increased to SEK 92.0 (83.6) million.

The subscription period of the series TO 1 warrants starts today

Stem cell company NextCell Pharma AB ("NXTCL") announces that today, 23rd of August 2018, marks the start of the subscription period of the series of TO 1 series warrants which were issued as part of the company's issue of units during the spring of 2017. The subscription period will end on the 13th of September 2018. Holders of the series TO 1 warrants are entitled to subscribe for a new share for each warrant at a price of SEK 5.00 per share. If all of the series TO 1 warrants are exercised, 2 860 940 new shares will be issued and NXTCL is receives approximately MSEK 14.3 before issue costs.

Diamyd Medical exercises all of its warrants in NextCell Pharma

Diamyd Medical invests another SEK 1.5 million in the stem cell company NextCell Pharma AB by exercising all of the Company’s warrants of the TO1 Series in NextCell Pharma. Diamyd Medical holds 296,800 warrants, corresponding to approximately 10.4 % of the total number of outstanding warrants.Diamyd Medical is one of the main shareholders of NextCell Pharma, with a shareholding of approximately 13.8%. At full utilization rate of all outstanding warrants of series TO 1, a total of 2 860 940, Diamyd Medical will after the warrants have been converted to shares, hold approximately 12.9% of

Fortum Foundation awards more than 680,000 euros in scholarships for global energy sector research

FORTUM CORPORATION ONLINE NEWS 23 August 2018  In 2018, Fortum Foundation awarded a total of more than 680,000 euros to 38 research projects. This year’s Fortum Foundation scholarship distribution event was held on 20 August 2018 at Neste Oyj’s Head Office in Keilaranta, Espoo. “Both founders of the Foundation, Fortum and Neste, are experiencing significant change in the business environment. The megatrends driving the change, like digitalisation, urbanisation, and changing consumer behaviour, are visible in the everyday life of people, e.g. in the electrification of transportation,

SimCorp reports revenue growth of 17% and EBIT margin of 22% in H1 2018

Company Announcement no. 11/2018  H1 2018 highlights: · Reported revenue was EUR 172.8m, an increase of 16.7% when compared with H1 2017, and an increase of 21.1% when measured in local currencies. As SimCorp Italiana, acquired in August 2017, accounted for 7.7%-points of the increase, organic revenue growth was 13.4%. · EBIT was EUR 37.4m compared with EUR 23.4m in H1 2017. EBIT stemming from SimCorp Italiana accounted for EUR 5.4m. Currency fluctuations impacted EBIT negatively by EUR 3.2m during the first half year.   · EBIT margin was 21.6% compared with 15.8% in H1

AstraZeneca PLC

23 August 2018 07:00 BST AstraZeneca provides update on AERISTO Phase IIIb trial for Bevespi Aerosphere in chronic obstructive pulmonary disease AstraZeneca today announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). In the trial, Bevespi Aerosphere demonstrated non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1) but did not demonstrate superiority on peak FEV1 or non-inferiority on

New CFO appointed for GARO

Helena Claesson has been appointed CFO for GARO AB and will be part of group management. Helena comes from Sensys Gatso Sweden AB, where she has been managing director since 2017. She has a Bachelor degree from Jönköping University and has during her 14 years at Sensys Gatso Group AB / Sensys Traffic AB held several positions, including financial director and acting managing director. Helena will take office as CFO no later than January 1, 2019, following Lars Kvarnsund's resignation in mid-October 2018. Rickard Blomqvist, board member of GARO, will take the role of acting CFO in GARO

Interim Report January – June 2018

Positive results of the BAN2401 Phase 2b study in early Alzheimer’s disease  April – June 2018 · Net revenues for the period amounted to SEK 52.3 million (32.0) · Operating profit amounted to SEK 6.4 million (2.5) · Profit for the period amounted to SEK 5.1 million (2.3) · Earnings per share were SEK 0.06 (0.04) · Cash flow from operating activities amounted to SEK -37.3 million (-27.6) January – June 2018 · Net revenues for the period amounted to SEK 104.6 million (58.2) · Operating profit amounted to SEK 25.3 million (3.9) · Profit for the period

Sale of shares in Boozt AB (publ)

Press release, 23 August 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Sunstone Technology Ventures Fund II K/S (“Sunstone”), Ferd AS (“Ferd”) and a group of key employees (including CEO and CFO) (the “key employees”) (together the “Sellers”) have sold 2,967,987 shares in Boozt AB (publ) (“Boozt”) through an accelerated bookbuilding process to Swedish and international institutional investors at a price of SEK 80.

Interim financial report - Cinnober Financial Technology AB (Publ)

January 1, 2018 – June 30, 2018Second quarter highlights · Net sales amounted to SEK 87.6 (91.8) million; the proportion of recurring revenue amounted to 72.6% (70.0%) of net sales. · EBITDA as reported for the quarter amounted to SEK -38.2 (-28.2) million. Adjusting for one-off items affecting comparability of SEK 6.8 million in the second quarter, adjusted (underlying) EBITDA amounted to SEK -31.4 million. This represents an improvement from the Q1/18 adjusted EBITDA figure of SEK -34.9 million. · The loss for the quarter amounted to SEK -7.7 (-28.9) million, with the result

DBP has signed an agreement of scientific and technical partnership with the Biochemistry cluster of ITMO University

Double Bond Pharmaceutical and the Biochemistry cluster SCAMT of ITMO University (St Petersburg, Russian Federation) have signed an agreement of scientific and technical partnership. “Reverse Innovation is an important part of our business strategy and competitive advantage, - comments Igor Lokot, CEO. – We are happy to broaden our partnership network with another experienced team for the efficient development of both novel and ongoing projects”. More about the Biochemistry cluster SCAMT of ITMO University: https://scamt.ifmo.ru/ This information is information that Double Bond

Tieto’s financial calendar 2019

Tieto Corporation          STOCK EXCHANGE RELEASE          23 August 2018 9.00 am EET 6 February Interim report 4/2018 and financial  statements bulletin for 2018 (8.00 am EET)By 28 Annual Report 2018 on Tieto's websiteFebruary21 March Annual General Meeting Tieto will publish three interim reports in 2019: 25 April Interim report 1/2019 (8.00 am EET)19 July Interim report 2/2019 (8.00 am EET)24 October   Interim report 3/2019 (8.00 am EET) For further information, please contactTanja Lounevirta, Head of Investor

Interim report Q2 2018

“STRONG GROWTH IN ALL AREAS”SECOND QUARTER 2018 · Revenues increased by 41.3% to EUR 6.0 million (EUR 4.3 million) · Organic growth amounted to 24.5% (7.7%) · Adjusted EBITDA increased by 25.4% to EUR 3.2 million (EUR 2.6 million), corresponding to a margin of 53.7% (60.5%). · Adjusted operating profit amounted to EUR 2.9 million (EUR 2.4 million), corresponding to a margin of 48.3% (56.6%) · Profit for the period amounted to EUR 0.2 million (EUR 1.5 million) · Earnings per share amounted to EUR 0.02 (EUR 8.55) before dilution · NDCs (New Depositing Customers)

Kamux Oyj: Kamux Corporation's Half Year Financial Report for January-June 2018

Kamux Corporation         Half Year Financial Report                  August 23, 2018 09:00 Kamux Corporation's Half Year Financial Report for January-June 2018 KAMUX'S ADJUSTED OPERATING PROFIT INCREASED BY 36.2% IN APRIL-JUNE 2018 The figures in parenthesis refer to the comparison period, i.e. the same period in the previous year, unless otherwise mentioned. April-June in brief - The number of cars sold increased by 15.7% to 11,433 cars (9,882) - Revenue increased by 17.2%, totaling EUR 128.0 million (109.2) - Gross profit increased by 25.7% to EUR 16.3 million (13.0),

TECHSTEP WINS CONTRACT WITH DIFI – THE NORWEGIAN GOVERNMENT’S AGENCY FOR PUBLIC MANAGEMENT AND EGOVERNMENT

Techstep has won a framework agreement with Difi, the Norwegian government’s Agency for public management and eGovernment. Under the agreement, Techstep will provide mobile solutions comprising mobile phones and tablets, related equipment, and operating and support services to Difis organisations and their employees. The agreement will be entered into with Difi’s Department of Public Procurement and will be signed shortly after the closing date for submission of complaints, which is due 3 September 2018. The potential contract value is NOK 200 million excluding options, with the majority

Strong start to 2018 for Zound Industries

Following on from a record close to 2017, Zound Industries has seen continued strong sales during the first six months of 2018. Net sales grew by 27 percent to 740 M SEK, compared to 585 M SEK for the same period last year.“To continue the success of 2017 is phenomenal. Our focus on building a solid foundation for future growth is paying off and we’re now looking forward to see what the second half of the year brings. We have great confidence in the company and in the team,” says Tommy Jacobson, Chairman of the Board at Zound Industries. This year has seen several new product launches

There are no items matching the current filter
There are no more items matching the current filter
Back to top